Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78180
Title:
Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
Authors:
Clayton, Julie
Abstract:
Radioimmunotherapy (RIT) is a new cancer therapy that uses monoclonal antibodies to deliver targeted radiation to cancer cells, allowing multiple sites of disseminated disease to be treated simultaneously, while limiting toxicity to normal healthy tissue. 90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin's lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y. Effective RIT demands a multidisciplinary approach to patient care, which places considerable emphasis on the role of the nurse. This review explores the role of the nurse in 90Y-ibritumomab tiuxetan therapy.
Affiliation:
Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. Julie.Clayton@christie-tr.nwest.nhs.uk
Citation:
Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy. 2003, 44 Suppl 4:S49-55 Leuk. Lymphoma
Journal:
Leukemia & Lymphoma
Issue Date:
2003
URI:
http://hdl.handle.net/10541/78180
PubMed ID:
15154742
Type:
Article
Language:
en
ISSN:
1042-8194
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorClayton, Julie-
dc.date.accessioned2009-08-21T12:08:22Z-
dc.date.available2009-08-21T12:08:22Z-
dc.date.issued2003-
dc.identifier.citationNursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy. 2003, 44 Suppl 4:S49-55 Leuk. Lymphomaen
dc.identifier.issn1042-8194-
dc.identifier.pmid15154742-
dc.identifier.urihttp://hdl.handle.net/10541/78180-
dc.description.abstractRadioimmunotherapy (RIT) is a new cancer therapy that uses monoclonal antibodies to deliver targeted radiation to cancer cells, allowing multiple sites of disseminated disease to be treated simultaneously, while limiting toxicity to normal healthy tissue. 90Y-ibritumomab tiuxetan was the first RIT to be approved for the treatment of relapsed and refractory B-cell non-Hodgkin's lymphoma (NHL), and consists of the anti-CD20 murine monoclonal antibody, ibritumomab, covalently bound to the linker tiuxetan, which securely chelates the radioactive isotope 90Y. Effective RIT demands a multidisciplinary approach to patient care, which places considerable emphasis on the role of the nurse. This review explores the role of the nurse in 90Y-ibritumomab tiuxetan therapy.en
dc.language.isoenen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshOncologic Nursing-
dc.subject.meshPrimary Nursing Care-
dc.subject.meshRadioimmunotherapy-
dc.subject.meshYttrium Radioisotopes-
dc.titleNursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. Julie.Clayton@christie-tr.nwest.nhs.uken
dc.identifier.journalLeukemia & Lymphomaen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.